Pharmacyclics, Inc. (NASDAQ:PCYC) released its financial report on May 2, 2014 for the period that ended on March 31, 2014. The company reported that the last quarter was a good tenure for it compared to a year back. Pharmacyclics, Inc. (NASDAQ:PCYC) announced that the total revenue generated for the quarter that ended on March 31, 2014 was $119.4 million. From the sales of IMBRUVICA™, the company accumulated net product revenue of approximately $56.2 million. In comparison, a quarter before the net product revenue from IMBRUVICA™ was $42.6 million. Within a span of three months, the biopharmaceutical company’s inventory for the distribution channel increased from $3.8 to $7.4 million. Pharmacyclics, Inc. (NASDAQ:PCYC) shares after opening at $ 86.87 moved to $96.00 on last trade day and at the end of the day closed at $95.18. Company price to sales ratio in past twelve months was calculated as 27.45 and price to cash ratio as 11.23. Pharmacyclics, Inc. (NASDAQ:PCYC) showed a positive weekly performance of 3.97%.
Westlake Chemical Corporation (NYSE:WLK) announced better than expected results for the first quarter driven by strong sales helped by its key products and increased volumes for its caustic, polyethylene, and building products besides Olefins division’s robust results.
The company earned a profit of $158.0 million or $1.18 a share, up 28% from $123.3 million or $0.92 a share in the year earlier quarter. On average, 9 analysts estimated the company to earn a profit of $1.13 per share. Westlake Chemical Corporation (NYSE:WLK) shares advanced 6.14% in last trading session and ended the day on $75.21. WLK return on equity ratio is recorded as 33.30% and its return on assets is 19.20%. Westlake Chemical Corporation (NYSE:WLK) yearly performance is 76787%.
ParkerVision, Inc. (NASDAQ:PRKR) announced that it has filed a second patent infringement complaint against Qualcomm Incorporated (Nasdaq:QCOM). The complaint, filed in the United States District Court for the Middle District of Florida, alleges that Qualcomm Incorporated, Qualcomm Atheros, Inc., HTC Corporation and HTC America, Inc. (collectively “Defendants”) have and continue to make, use, import into the United States, and sell integrated circuits that infringe seven ParkerVision patents. These patents, which were granted for different technologies than the patents in ParkerVision’s first infringement case against Qualcomm, relate to radio frequency (“RF”) up-conversion of electromagnetic signals, systems for control of multi-mode, multi-band communications, baseband innovations including control and system calibration, and wireless protocol conversion. ParkerVision is seeking unspecified monetary damages from the Defendants as well as a permanent injunction. ParkerVision is also seeking a finding of willful infringement against Qualcomm based on its alleged prior knowledge of certain of the patents in this case. ParkerVision, Inc. (NASDAQ:PRKR) shares moved up 6.10% in last trading session and was closed at $5.39, while trading in range of $ 3.48 – 3.60. ParkerVision, Inc . (NASDAQ:PRKR) year to date (YTD) performance is 7668%.
Specifically, CEO Fusen Ernie Chen bought 20,000 shares of Mattson Technology stock in a transaction dated Thursday, May 1st. The shares were purchased at an average cost of $1.93 per share, with a total value of $38,600.00. Mattson Technology, Inc. (NASDAQ:MTSN) weekly performance is -0.50%. On last trading day company shares ended up $1.99. Mattson Technology, Inc. (NASDAQ:MTSN) distance from 50-day simple moving average (SMA50) is -16.29%. Analysts mean target price for the company is $3.69.